TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07660055: Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

Sponsor: Novartis Pharmaceuticals · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 156 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07660055 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07660055 Rescue Dossier →